Trial Profile
A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PDC31 in Patients With Primary Dysmenorrhea.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2015
Price :
$35
*
At a glance
- Drugs THG 113 (Primary)
- Indications Dysmenorrhoea
- Focus Adverse reactions; First in man
- Sponsors PDC Biotech
- 20 Sep 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 20 Feb 2012 Planned End Date changed from 1 Apr 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
- 09 Jan 2012 Planned End Date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.